These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


248 related items for PubMed ID: 16034840

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ductus venosus assessment at the time of nuchal translucency measurement in the detection of fetal aneuploidy.
    Borrell A, Martinez JM, Serés A, Borobio V, Cararach V, Fortuny A.
    Prenat Diagn; 2003 Nov; 23(11):921-6. PubMed ID: 14634979
    [Abstract] [Full Text] [Related]

  • 3. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Maiz N, Valencia C, Kagan KO, Wright D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2009 May; 33(5):512-7. PubMed ID: 19338027
    [Abstract] [Full Text] [Related]

  • 4. Screening for aneuploidy in the first trimester by assessment of blood flow in the ductus venosus.
    Mavrides E, Sairam S, Hollis B, Thilaganathan B.
    BJOG; 2002 Sep; 109(9):1015-9. PubMed ID: 12269675
    [Abstract] [Full Text] [Related]

  • 5. Assessment of the ductus venosus, tricuspid blood flow and the nasal bone in second-trimester screening for trisomy 21.
    Stressig R, Kozlowski P, Froehlich S, Siegmann HJ, Hammer R, Blumenstock G, Kagan KO.
    Ultrasound Obstet Gynecol; 2011 Apr; 37(4):444-9. PubMed ID: 20645398
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH.
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [Abstract] [Full Text] [Related]

  • 11. Normal range of intracranial translucency in healthy Turkish pregnancies and its association with first trimester maternal serum biochemistry and ductus venosus pulsatility index. .
    Artunc-Ulkumen B, Pala HG, Uyar Y, Bulbul-Baytur Y, Koyuncu FM.
    Ginekol Pol; 2014 Oct; 85(10):738-41. PubMed ID: 25546923
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Observational study comparing the performance of first-trimester screening protocols for detecting trisomy 21 in a North Indian population.
    Kaul A, Singh C, Gupta R, Arora N, Gupta A.
    Int J Gynaecol Obstet; 2017 Apr; 137(1):14-19. PubMed ID: 28099747
    [Abstract] [Full Text] [Related]

  • 14. Anticipating twin-twin transfusion syndrome in monochorionic twin pregnancy. Is there a role for nuchal translucency and ductus venosus blood flow evaluation at 11-14 weeks?
    Matias A, Montenegro N, Areias JC.
    Twin Res; 2000 Jun; 3(2):65-70. PubMed ID: 10918616
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A, Grunewald C, Saltvedt S, Valentin L, Almström H.
    Acta Obstet Gynecol Scand; 2006 Jun; 85(5):534-8. PubMed ID: 16752230
    [Abstract] [Full Text] [Related]

  • 17. [Predictive value for fetal outcome of Doppler velocimetry of the ductus venosus between the 11th and the 14th gestation week].
    Gollo CA, Murta CG, Bussamra LC, Santana RM, Moron AF.
    Rev Bras Ginecol Obstet; 2008 Jan; 30(1):5-11. PubMed ID: 19142536
    [Abstract] [Full Text] [Related]

  • 18. First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing.
    Kagan KO, Wright D, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2015 Jan; 45(1):42-7. PubMed ID: 25307357
    [Abstract] [Full Text] [Related]

  • 19. A preliminary retrospective study about the relationship between ductus venosus Doppler indices, nuchal translucency (NT) and biochemical markers in the first and second trimester screening tests.
    Demirturk F, Caliskan AC, Aytan H, Sahin S.
    Gynecol Endocrinol; 2012 May; 28(5):378-81. PubMed ID: 22364171
    [Abstract] [Full Text] [Related]

  • 20. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O, Auer M, Gerovassili A, Spencer K, Nicolaides KH.
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 13.